Syndax Pharmaceuticals director plans $115K share sale

The notice identifies NASDAQ as the exchange and Morgan Stanley Smith Barney LLC as broker for the proposed sale.

Rhea-AI Filing Summary

Syndax Pharmaceuticals, Inc. (SNDX) director Dennis G. Podlesak reported an intended sale of 8,000 common shares, with an approximate sale date of October 29, 2026. The notice lists an aggregate market value of $114,560.00 and says the shares were acquired from the issuer through exercise of stock options, with cash payment. Morgan Stanley Smith Barney LLC is named as the broker.

Key Figures

Shares to be sold: 8,000 shares Aggregate market value: $114,560.00 Approximate sale date: October 29, 2026 +1 more

4 metrics

Shares to be sold 8,000 shares Common shares in the proposed sale

Aggregate market value $114,560.00 Proposed sale

Approximate sale date October 29, 2026 Proposed sale

Shares outstanding 89,297,086 shares Issuer shares outstanding

Key Terms

Rule 144, Exercise of Stock Options

2 terms

Rule 144 regulatory

"the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Stock Options technical

"Exercise of Stock Options"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SNDX shares does Dennis Podlesak plan to sell?

The notice reports an intended sale of 8,000 common shares by director Dennis G. Podlesak. It lists an aggregate market value of $114,560.00 and an approximate sale date of October 29, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/29/2026 - 04:20 PM EDT Accepted by SEC EDGAR 10/29/2026 - 04:20 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001314595
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Syndax Pharmaceuticals, Inc.
SEC File Number	001-37708
Address of Issuer	730 Third Avenue, 9th Floor New York NEW YORK 10017
Phone	7814191400
Name of Person for Whose Account the Securities are To Be Sold	DENNIS G PODLESAK
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	8000	114560.00	89297086	10/29/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/29/2026	Exercise of Stock Options	Issuer			8000	10/29/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	10/29/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/15/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	DENNIS G PODLESAK
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)